Obesity Management Resources
The AASM Obesity Management Task Force compiled these resources to help equip sleep medicine professionals to manage obesity in patients who have sleep disorders. Obesity management options expanded in December 2024, when the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
The task force also compiled obesity management resources for patients, which are available on the Sleep Education website.
The International Classification of Sleep Disorders (ICSD) describes a variety of associations between obesity and sleep disorders.
- The major predisposing factor for obstructive sleep apnea (OSA) in adults is excess body weight. In the pediatric population, obesity may be a more important risk factor for OSA in older children and adolescents but is also relevant in younger children.
- Snoring is a cardinal symptom of OSA. Snoring is most common in adult men and is also linked to obesity.
- Obesity hypoventilation syndrome is characterized by obesity and daytime hypercapnia, which worsens during sleep and is often associated with severe arterial oxygen desaturation. The majority of these patients have comorbid OSA.
- Epidemiological studies have shown that obesity is common in narcolepsy type 1. Around disease onset, an unexplained increase in body weight is often observed, particularly when disease onset is more acute, as is often the case in children.
- Night shift work is associated with obesity; women are affected more than men.
- Adverse health consequences of sleep-related eating disorder (SRED) include obesity (including morbid obesity resulting in bariatric surgery). SRED may complicate the postoperative course of patients undergoing bariatric surgery.
- The most common symptoms of sleep-related gastroesophageal reflux are heartburn and regurgitation, and predictors of heartburn during sleep include the presence of abdominal obesity.
- Truncal-abdominal obesity may further contribute to the likelihood of sleep-related myocardial ischemia/infarction.
Several AASM practice standards include guidance related to obesity.
- The “Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea” indicates that diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation that identifies medical conditions associated with increased risk for OSA, such as obesity.
- The “Practice parameters for the respiratory indications for polysomnography in children” recommend that polysomnography (PSG) is indicated following adenotonsillectomy to assess for residual OSA in children with preoperative evidence for obesity.
- The guidance statement on “Use of polysomnography and home sleep apnea tests for the longitudinal management of obstructive sleep apnea in adults” indicates that follow-up PSG or a home sleep apnea test (HSAT) may be used if clinically significant weight gain or loss (i.e., 10 to 20%) has occurred since diagnosis of OSA or initiation of its treatment.
- The clinical guideline for “Manual titration of positive airway pressure in patients with obstructive sleep apnea” suggests that a higher starting continuous positive airway pressure (CPAP) may be selected for patients with an elevated body mass index.
- The “Practice parameters for the medical therapy of obstructive sleep apnea” indicate that dietary weight loss should be combined with a primary treatment for OSA, and bariatric surgery may be adjunctive in the treatment of OSA in obese patients.
- The clinical practice guideline for “Referral of adults with obstructive sleep apnea for surgical consultation” recommends that clinicians discuss referral to a bariatric surgeon with adults with OSA and obesity (class II/III, BMI ≥35 kg/m2) who are intolerant or unaccepting of positive airway pressure (PAP) as part of a patient-oriented discussion of alternative treatment options.
Featured
Canadian adult obesity clinical practice guideline
Developed by Obesity Canada and the Canadian Association of Bariatric Physicians and Surgeons, this guideline contains 19 open-source chapters that will be updated as new evidence arises. Most recently, the chapter on pharmacotherapy in obesity management was updated in 2025 to reflect the latest research and treatment options.
| Year | Title | Organization | Link |
|---|---|---|---|
| 2026 | Use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults | World Health Organization | View guideline |
| 2025 | Management of adult overweight and obesity | U.S. Department of Veterans Affairs and Department of Defense | View guideline |
| 2025 | Canadian adult obesity clinical practice guideline | Obesity Canada and the Canadian Association of Bariatric Physicians and Surgeons | View guideline |
| 2025 | Canadian pediatric obesity clinical practice guideline | Obesity Canada | View guideline |
| 2023 | Evaluation and treatment of children and adolescents with obesity | American Academy of Pediatrics | View guideline |
| 2022 | Pharmacological interventions for adults with obesity | American Gastroenterological Association | View guideline |
| 2021 | Referral of adults with obstructive sleep apnea for surgical consultation | American Academy of Sleep Medicine | View guideline |
| 2018 | The role of weight management in the treatment of adult obstructive sleep apnea | American Thoracic Society | View guideline |
| 2018 | Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults | U.S. Preventive Services Task Force | View guideline |
| 2016 | Comprehensive clinical practice guidelines for medical care of patients with obesity | American Association of Clinical Endocrinologists and American College of Endocrinology | View guideline |
| 2015 | European guidelines for obesity management in adults | Obesity Facts | View guideline |
| 2013 | Guideline for the management of overweight and obesity in adults | American College of Cardiology, American Heart Association, and The Obesity Society | View guideline |
Featured
Algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease – 2025 update
Published in 2025 by the American Association of Clinical Endocrinology, this consensus statement provides visual guidance in graphic algorithms to assist health care professionals and patients in shared decision making to improve care and achieve health goals.
| Year | Title | Organization | Link |
|---|---|---|---|
| 2025 | Algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease – 2025 update | American Association of Clinical Endocrinology | View statement |
| 2025 | Nutritional priorities to support GLP‐1 therapy for obesity | American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society | View statement |
| 2025 | Obesity management in primary care: A joint clinical perspective and expert review | Obesity Medicine Association and American College of Osteopathic Family Physicians | View statement |
| 2025 | Definition and diagnostic criteria of clinical obesity | The Lancet Diabetes & Endocrinology Commission | View statement |
| 2025 | Dietary guidelines for Americans | U.S. Department of Health and Human Services and U.S. Department of Agriculture | View statement |
| 2023 | Definitions and clinical practice guidelines for obesity management — an international Delphi study | International Federation for the Surgery and Other Therapies for Obesity | View statement |
| 2020 | Waist circumference as a vital sign in clinical practice | International Atherosclerosis Society and International Chair on Cardiometabolic Risk | View statement |
| 2018 | Physical activity guidelines for Americans, 2nd edition | U.S. Department of Health and Human Services | View statement |
| 2017 | Adiposity-based chronic disease as a new diagnostic term | American Association of Clinical Endocrinology and American College of Endocrinology | View statement |
Featured
Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review
Published in 2025 in the Journal of Clinical Sleep Medicine, this narrative review concludes that SGLT2 inhibitors, GLP-1 receptor agonists, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnea index and weight.
| Year | Title | Journal | Link |
|---|---|---|---|
| 2025 | Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review | Journal of Clinical Sleep Medicine | View review |
| 2025 | Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea | Current Opinion in Pulmonary Medicine | View review |
| 2025 | Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus | Journal of Translational Medicine | View review |
| 2025 | Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions | Frontiers in Neurology | View review |
| 2025 | Obstructive sleep apnea: An evolving therapeutic landscape with an emerging role for incretin-based therapies | Advances in Therapy | View review |
| 2025 | Emerging pharmacotherapies for obesity: A systematic review | Pharmacological Reviews | View review |
| 2025 | Obesity and sleep disorders: A bidirectional relationship | Nutrition, Metabolism and Cardiovascular Diseases | View review |
| 2025 | The integration of lifestyle modification advice and diet and physical exercise interventions: Cornerstones in the management of obesity with incretin mimetics | Obesity Facts | View review |
| 2025 | Effectiveness of behavioural and psychological interventions for managing obesity in children and adolescents | Pediatric Obesity | View review |
| 2024 | The association of weight loss from anti-obesity medications or bariatric surgery and apnea-hypopnea index in obstructive sleep apnea | Obesity Reviews | View review |
| 2024 | Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments | Sleep Medicine Reviews | View review |
| 2024 | Effectiveness of surgical interventions for managing obesity in children and adolescents | Pediatric Obesity | View review |
| 2024 | Effectiveness of pharmacological interventions for managing obesity in children and adolescents | Pediatric Obesity | View review |
| 2023 | Sleep apnea, obesity, and diabetes — an intertwined trio | Current Diabetes Reports | View review |
| 2023 | Obesity management in adults | JAMA | View review |
| 2023 | Dietary and lifestyle risk factors of obesity among young adults | Current Nutrition Reports | View review |
| 2022 | Are individual or group interventions more effective for long-term weight loss in adults with obesity? | Clinical Obesity | View review |
| 2021 | Fear-related barriers to physical activity among adults with overweight and obesity | Obesity Reviews | View review |
| 2019 | Weight management in young adults: Systematic review of electronic health intervention components and outcomes | Journal of Medical Internet Research | View review |
Featured
Tirzepatide for the treatment of obstructive sleep apnea and obesity
Published in 2024 in the New England Journal of Medicine, these two phase 3, double-blind, randomized, controlled trials found that participants who received tirzepatide had a clinically meaningful change in sleep-disordered breathing and alleviation of perceived sleep disturbance and sleep-related impairment, as well as reductions in common obstructive sleep apnea-related cardiovascular risk factors.
| Title | Journal | Link |
|---|---|---|
| Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide | Journal of Clinical Sleep Medicine | View article |
| Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial | Nature Medicine | View article |
| Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity | Sleep Medicine | View article |
| Clinical impact of tirzepatide on patients with OSA and obesity | CHEST | View article |
| Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score matched study | Diabetes Research and Clinical Practice | View article |
| Tirzepatide and semaglutide for the treatment of obstructive sleep apnea and obesity: a retrospective analysis | Medical Research Archives | View article |
| Tirzepatide for the treatment of obstructive sleep apnea and obesity | New England Journal of Medicine | View article |
| Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial | Contemporary Clinical Trials | View article |
Featured
Obesity Education Hub
Developed by Obesity Canada, the Obesity Education Hub offers the tools, strategies, and clinical insights that health care professionals need to confidently support people living with obesity.
| Year | Title | Source | Link |
|---|---|---|---|
| 2026 | Obesity Education Hub | Obesity Canada | View resource |
| 2026 | Obesity resources for healthcare professionals | Obesity Canada | View resource |
| 2026 | Obesity resource library | Obesity Action Coalition | View resource |
| 2026 | Obesity medicine education | Obesity Medicine Association | View resource |
| 2026 | Obesity education | The Obesity Society | View resource |
| 2026 | Resources for healthcare professionals | American Society for Metabolic and Bariatric Surgery | View resource |
| 2026 | Obesity medicine exam eligibility and requirements | American Board of Obesity Medicine | View resource |
| 2025 | Managing adverse effects of incretin-based medications for obesity | JAMA | View resource |
| 2025 | Talk to your patients and clients about healthy eating routines | Office of Disease Prevention and Health Promotion | View resource |
| 2025 | Zepbound® prior authorization resource guide | Lilly | View resource |
| 2025 | Understanding weight stigma and strategies to improve patient care (VIDEO) | Uconn Rudd Center and Lilly | View resource |
| 2025 | Integrating diet and physical activity when prescribing GLP-1s — lifestyle factors remain crucial | JAMA Internal Medicine | View resource |
| 2023 | Ways to reduce weight stigma in clinician-patient communication | Uconn Rudd Center and Lilly | View resource |
| 2023 | Approach the patient with obstructive sleep apnea and obesity | Journal of Clinical Endocrinology & Metabolism | View resource |
| 2022 | The link between obesity and obstructive sleep apnea | American Academy of Sleep Medicine | View resource |
| 2020 | Reducing stigma when talking to patients about weight | Uconn Rudd Center for Food Policy and Health | View resource |
| 2020 | Weight can’t wait: Guide for the management of obesity in the primary care setting | Milken Institute School of Public Health The George Washington University | View resource |
| 2014 | Why weight? A guide to discussing obesity & health with your patients | STOP Obesity Alliance | View resource |
| 2012 | STOP-Bang Questionnaire | University of Toronto | View resource |
Updated March 23, 2026
